Payment overview · 2025
General Payments
$839.87
43 reported records · 15 companies
Healthcare provider profile · identity verified
Arlene Donowitz, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CHATTANOOGA, TN · NPI 1548247109
Verified facts
What the public records show
CMS Open Payments records show Arlene Donowitz, MD received $839.87 in general payments during 2025 across 43 reported records.
PFIZER INC. accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $176.24 | 21.0% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $142.41 | 17.0% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $112.67 | 13.4% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $109.27 | 13.0% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $60.00 | 7.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.58 | 5.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.94 | 3.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.71 | 3.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.94 | 3.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.70 | 2.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.97 | 2.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.74 | 2.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.36 | 2.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.22 | 2.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.12 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $779.87 | 42 |
| Education | $60.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $128.50 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $128.50 | 6 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $115.66 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $112.67 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $109.27 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $98.65 | 7 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $98.65 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $44.91 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $41.58 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $32.94 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.71 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.71 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 78 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
72 | 18 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
42 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 655 | 181 |
| Atorvastatin Calcium | Atorvastatin Calcium | 585 | 172 |
| Amlodipine Besylate | Amlodipine Besylate | 582 | 167 |
| Losartan Potassium | Losartan Potassium | 382 | 108 |
| Omeprazole | Omeprazole | 377 | 113 |
| Hydrochlorothiazide | Hydrochlorothiazide | 318 | 98 |
| Lisinopril | Lisinopril | 295 | 92 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 243 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 71 |
| Gabapentin | Gabapentin | 226 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 199 | 57 |
| Potassium Chloride | Potassium Chloride | 189 | 64 |
| Metformin Hcl | Metformin Hcl | 177 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 49 |
| Spironolactone | Spironolactone | 141 | 52 |
| Sertraline Hcl | Sertraline Hcl | 139 | 46 |
| Trazodone Hcl | Trazodone Hcl | 131 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 66 |
| Mounjaro | Tirzepatide | 126 | 21 |
| Glimepiride | Glimepiride | 117 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 38 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 108 | 35 |
| Furosemide | Furosemide | 105 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 32 |
| Montelukast Sodium | Montelukast Sodium | 97 | 32 |
| Bupropion Xl | Bupropion Hcl | 96 | 29 |
| Ozempic | Semaglutide | 93 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 30 |
| Lorazepam | Lorazepam | 90 | 21 |
| Allopurinol | Allopurinol | 87 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 25 |
| Buspirone Hcl | Buspirone Hcl | 83 | 30 |
| Alprazolam | Alprazolam | 81 | 13 |
| Valsartan | Valsartan | 79 | 20 |
| Eliquis | Apixaban | 78 | 23 |
| Estradiol | Estradiol | 76 | 28 |
| Simvastatin | Simvastatin | 76 | 23 |
| Ondansetron Odt | Ondansetron | 75 | 32 |
| Atenolol | Atenolol | 72 | 22 |
| Synthroid | Levothyroxine Sodium | 72 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 19 |
| Carvedilol | Carvedilol | 68 | 18 |
| Alendronate Sodium | Alendronate Sodium | 64 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 17 |
| Meloxicam | Meloxicam | 59 | 28 |
| Ezetimibe | Ezetimibe | 58 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 57 | 15 |
| Amoxicillin | Amoxicillin | 56 | 51 |
| Azithromycin | Azithromycin | 54 | 50 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | 18 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Irbesartan | Irbesartan | 51 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 48 | 15 |
| Mirtazapine | Mirtazapine | 46 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 15 |
| Cefuroxime | Cefuroxime Axetil | 43 | 38 |
| Tramadol Hcl | Tramadol Hcl | 43 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 42 | 41 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Celecoxib | Celecoxib | 40 | 17 |
| Valacyclovir | Valacyclovir Hcl | 40 | 23 |
| Metformin Hcl Er | Metformin Hcl | 39 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | 11 |
| Clonidine Hcl | Clonidine Hcl | 37 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 28 |
| Donepezil Hcl | Donepezil Hcl | 35 | 12 |
| Jardiance | Empagliflozin | 35 | suppressed |
| Prednisone | Prednisone | 35 | 25 |
| Famotidine | Famotidine | 34 | 15 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 30 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 21 |
| Torsemide | Torsemide | 28 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 23 |
| Meclizine Hcl | Meclizine Hcl | 25 | 11 |
| Estradiol (Twice Weekly) | Estradiol | 24 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 15 |
| Temazepam | Temazepam | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Colchicine | Colchicine | 19 | 11 |
| Trulicity | Dulaglutide | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Benzonatate | Benzonatate | 14 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Teriparatide | Teriparatide | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $839.87 · 43 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, CAPVAXIVE, COMIRNATY, ELIQUIS, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, GVOKE HYPOPEN, Kerendia, LEQVIO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SHINGRIX, UBRELVY, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error